Drugs /

recombinant human interleukin-15

Back to Drugs List

Overview

NCI Definition [1]:
A recombinant agent that is chemically identical or similar to the endogenous form of the human cytokine interleukin-15 (IL-15) with immunomodulating activity. IL-15, secreted by mononuclear phagocytes (and some other cell types) following viral infection, regulates T and natural killer cell activation and proliferation. This cytokine induces activation of transcription activators STAT3, STAT5, and STAT6 via JAK kinase signal transduction pathways in mast cells, T cells, and dendritic epidermal T cells. IL-15 and interleukin-2 (IL-2) are structurally similar and share many biological activities; both may bind to common hematopoietin receptor subunits, negatively regulating each other's activity. CD8+ memory T cell number has been shown to be regulated by a balance between IL-15 and IL-2.

Clinical Trials

View Clinical Trials for recombinant human interleukin-15

Recombinant human interleukin-15 has been investigated in 6 clinical trials, of which 5 are open and 1 is closed. Of the trials investigating recombinant human interleukin-15, 5 are phase 1 (4 open) and 1 is phase 2 (1 open).

MS4A1 Expression, PD-L1 Expression (IC >= 5%), and TNFRSF8 Expression are the most frequent biomarker inclusion criteria for recombinant human interleukin-15 clinical trials.

Adult T-cell leukemia/lymphoma, chronic lymphocytic leukemia, and clear cell renal cell carcinoma are the most common diseases being investigated in recombinant human interleukin-15 clinical trials [2].

Top Biomarker Inclusion Criteria for Open Clinical Trials Investigating Recombinant Human Interleukin-15
Top Biomarker Inclusion Criteria for Closed Clinical Trials Investigating Recombinant Human Interleukin-15
This graph displays the 20 most frequently occurring biomarkers curated on clinical trials investigating recombinant human interleukin-15 and the cancer types associated with these biomarkers. These numbers are derived from a set of 5,956 clinical trials for which biomarker status defines treatment.

Drug Details

Synonyms [2]:
interleukin 15, ril15, interleukin 15, il15, recombinant interleukin-15, recombinant human interleukin-15, rhil-15
NCIT ID [1]:
C1545

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/. [2018-07-30] [2018-08-02].

2. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.